Introduction
Adrenocorticotropic hormone (ACTH), or corticotropin, is a pituitary poly peptide hormone consisting of 39 amino acids (ACTH ). 1 It is an important component of the hypothalamic-pituitary-adrenal (HPA) axis and has a pivotal role in sus taining homeostasis of the neuroimmuno endocrine system. 1 In the 1950s and early 1960s, ACTH was widely used for the treat ment of childhood nephrotic syndrome. [2] [3] [4] Subsequent clinical studies demonstrated that ACTH therapy induced remission of proteinuria in patients with nephrotic syndrome who were refractory to gluco corticoid and/or immunosuppressive thera pies, 5, 6 suggesting that ACTH has prominent antiproteinuric and reno protective effects that are not entirely explained by its steroido genic actions. Nevertheless, the exact mechanism underlying this anti proteinuric action remains largely unknown and the precise pathobiology underlying the function of ACTH as a renoprotective agent in patients with proteinuric nephropathies remains elusive. This Perspectives article presents a comprehensive overview of the biophysiology of ACTH, the effects of ACTH on proteinuric renal diseases, and the molecular mechanisms likely to be involved in its therapeutic action, with an emphasis on its melanocortin effects. As a potent physiological agonist of melano cortin system that could directly target renal parenchymal cells, such as podocytes, ACTH might serve as a promising therapy for nephrotic glomerulopathies.
Biophysiology of ACTH
The melanocortin system ACTH is one of several physiologically active peptides (Figure 1a ) that are syn thesized by proteolytic cleavage of the pre cursor peptide preproopiomelanocortin (prePOMC). 1 A major component of the HPA axis, ACTH is produced by cortico trophs in the anterior lobe of the pituitary gland. 1 ACTH stimulates the adrenal cortex to produce cortisol in response to stress and, as such, transmits vital information from the brain to the rest of the mammalian body ( Figure 1b) . In addition to governing steroidogenesis, ACTH is also an important physiological agonist of the melanocortin system. 7, 8 This system comprises multiple components, including five class A guanine nucleotidebinding protein (G protein) coupled melanocortin receptors (MCRs) MC1R-MC5R; peptide agonists derived from POMC; and endogenous antagonists ( Table 1 , Box 1). 7, 8 The five MCRs each have a distinct tissue distribution, convey signaling of different melano cortins and exert varying biological activities (Table 1) . 8 Receptorbinding studies have revealed that all five MCRs show a strong affinity for ACTH, thereby establishing the potential for this hormone to activate these receptors. 9 MCRs are expressed in kidney cells, [10] [11] [12] [13] [14] [15] which indicates that the kidney is a target organ for the effects of ACTH.
Physiological function of ACTH
In addition to the adrenal effects of ACTH, that is, its steroidogenic and adrenotropic activities, ACTH exerts a multifaceted extra adrenal action that is mediated by the dif ferent MCRs present in peripheral tissues and the central nervous system. ACTH has a lipostatic effect and stimulates lipolysis. 16 Indeed, ACTH deficiency leads to visceral obesity and causes conversion of brown adipose tissue to white adipose tissue. 16 Moreover, ACTH administration to both healthy humans and patients with dys lipidemia lowers the levels of plasma lipids, including total cholesterol, LDLcholesterol, phospholipids and triglycerides. 17, 18 Additionally, administration of the com plete ACTH molecule (ACTH ) produces a marked and rapid increase in the levels of plasma insulin, 19 which is consistent with an insulin secretagogue effect. This insulino tropic action is exerted by corticotropinlike intermediate peptide (CLIP), also known as the ACTH 18-39 fragment (Figure 1a ). 19 ACTH also has various other peripheral endocrine activities: regulation of skin and hair pigmentation, modulation of sebaceous gland function, and antiinflammatory and immuno modulatory functions (Table 1) .
Synthetic versus natural ACTH
Currently, two products that contain ACTH are commercially available. The first is an
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ACTH gel (HP Acthar Gel ® , Questcor Pharmaceuticals, NY, USA), which is a proprietary mixture isolated from porcine pituitary extracts. The major component of this gel is ACTH , which is likely to be the active principle, but it also contains a number of other potentially bio active POMCderived peptides (Questcor, per sonal communication). The ACTH gel is the only longacting ACTH product avail able in the USA and is approved by the FDA to induce diuresis or remission of protein uria in patients with nephrotic syndrome of the idiopathic type (without uremia) and nephrotic syndrome owing to lupus ery thematosus. The second product is a syn thetic, truncated ACTH analogue, referred to as tetracosactide or tetra copeptide, which consists of the first 24 amino acids 1 of the native hormone (ACTH ). This synthetic analogue is available as a short acting formula tion (cosyntropin) that is used solely to assess adrenal gland func tion. Outside the USA, ACTH is also available in a longacting formulation (syn acthen). Although synthetic ACTH has often been presumed to possess the same therapeutic profile as ACTH gel, a growing body of evidence suggests that these syn thetic analogues are different from natural ACTH in terms of their pharmacokinet ics, pharmaco dynamics and physiologic actions. 20, 21 For example, the βcell tropic and insulinotropic effect of the endog enous hormone resides in the Cterminus of ACTH 1-39 , 19 which is omitted from the synthetic analogue but is retained in the ACTH gel. Moreover, other pharmaco logically active molecules derived from POMC, including other melanocortin peptides, might also exist in the naturally derived ACTH gel but be absent from the synthetic formulation and this possibility warrants further investigation.
Therapeutic effects of ACTH

Preclinical evidence
The renoprotective effect of melanocortins on the kidney, in particular αmelanocyte stimulating hormone (MSH) (Box 1), has been reproducibly demonstrated in various animal models of acute kidney injury (AKI), 22 including ischemic reper fusion injury, 23 renal toxicity 24 and ure teral obstruction. 25 Indeed, work from my research group indicates that pretreatment with ACTH gel substantially attenuates tumor necrosis factor (TNF)induced AKI in rats. 26 Even at low doses, ACTH gel pre treatment normalized systemic and renal hemodynamics, significantly improved kidney function and increased survival. Renal histological injury was also pre vented by ACTH gel. 26 Mechanistically, the beneficial effect of ACTH gel was associated with a reduction in renal inflammation and apoptosis-two important patho genetic processes that are involved in AKI. 26 Thus, ACTH gel might represent a novel therapeutic strategy to prevent or treat AKI.
In animal models of chronic kidney disease (CKD), ACTH also has a potent role in controlling proteinuria, ameliorating histo logical signs of renal injury and retard ing the progression of kidney dysfunction. For example, rats with passive Heymann nephritis treated with synthetic ACTH showed a significant reduction in protein uria, which correlated with improved glomerular morphology and podocyte ultrastructure. 10 Our group has consis tently demonstrated evidence for a direct protective effect of ACTH gel on podocytes in subtotally nephrectomized rats-a stan dard model of secondary focal segmental glomerulosclerosis (FSGS) and progres sive CKD. 11 After subtotal renal ablation, these rats received ACTH gel every other day for 5 weeks. This treatment markedly diminished urinary protein excretion (by ~50%) and preserved kidney function as measured by increased renal plasma flow, improved inulin clearance rate and reduced serum creatinine levels. 11 Histologically, g l o m e r u l o s c l e r o s i s a n d t u b u l o interstitial fibrosis, renal inflamma tion, tubular atrophy, and tubular epithelialmesenchymal trans differentiation all improved. 11 As gluco corticoid therapy exacerbates proteinuria and glomerulo sclerosis in this model, 27 these beneficial effects of ACTH gel are unlikely to result from steroidogenesis. Instead, my research group found evidence of direct protective effects of ACTH gel treatment on podo cytes in the remnant glomeruli. These effects included notable reductions in foot process effacement and podocyte apop tosis, and amelioration of the decline in glomerular expression of podocyte markers, including vimentin, nephrin, podocin and the trans cription factor WT1. 11 These find ings suggest that ACTH gel has direct pro tective effects on podocytes in progressive glomerulopathies. Overall, therefore, these preclinical studies indicate that ACTH has a kidneyprotective effect in experimental models of AKI and CKD.
Clinical observations
Several studies have demonstrated that ACTH gel and ACTH 1-24 improve protein uria in adult patients with nephrotic syn drome caused by proteinuric nephro pathies, including idiopathic membranous nephro pathy (IMN). 5, 6, 10, 18, [28] [29] [30] [31] [32] [33] The anti proteinuric effect of ACTH 1-24 treatment was high lighted in a doseescalation study conducted in adults with nephrotic syndrome owing to IMN. The optimal dose was estimated to be 1 mg twice per week, taking both the thera peutic effects and the modest adverse effects of ACTH into considera tion. 8 Patients on ACTH 1-24 therapy attained signifi cant improvements in serum lipoprotein pro files, urine protein excretion and glomeru lar function. An openlabel, prospective, randomized, controlled trial has been con ducted to assess the efficacy and safety of a 12month course of synthetic ACTH therapy in 32 patients with nephrotic syn drome. 30 The ACTH 1-24 therapy was com pared with methyl prednisolone alternated with a cytotoxic agent (chlorambucil or cytoxan) in patients with biopsyproven IMN. Comparable response rates were observed: 75% of patients treated with the immunosuppressive regimen and 83% of ACTH 1-24 treated patients experienced complete or partial remission of nephrotic syndrome, and both groups had a compar able magnitude of dyslipidemia correction.
In an observational study, sustained remis sion of nephrotic syndrome was found in five patients with IMN treated with ACTH 1-24 for 12 months with a followup period of up to 26 months. 32 The results of a study published as an abstract in 2009 showed that ACTHinduced remission of proteinuria in patients with IMN was associated with a reduction in the levels of autoantibody against Mtype phospholipase A2 receptor (PLA2R), 34 which is a major target antigen in this disease. 35 Striking antiproteinuric effects of ACTH 1-24 have also been found in patients with nephrotic kidney diseases other than IMN, includ ing FSGS, proliferative glomerulonephritis and hereditary nephropathy, 28 implying that the therapeutic effect of ACTH is not dependent on the type of glomerular injury, but is probably mediated by a general glomeruloprotective mechanism.
Similar antiproteinuric and renoprotec tive properties were also observed with ACTH gel in patients with various protein uric nephropathies. One study included 21 patients with treatmentrefractory nephrotic syndrome associated with a variety of diagnoses, including membra nous nephropathy, membranoprolifera tive glomerulonephritis, FSGS, minimal change disease, lupus nephritis (class V) and IgA nephropathy. 33 The most frequent treatment regimen was 80 IU of ACTH gel injected subcutaneously twice per week for 6 months. A total of 11 patients (52%) achieved complete or partial remission of proteinuria. Of note, 82% of the patients with membranous nephropathy achieved remission (27% complete remission and 55% partial remission), despite having pre viously failed to respond to a mean of 2.4 immunosuppressive treatment regimens, denoting that ACTH gel is a viable therapy for resistant nephrotic syndrome associated with membranous nephropathy. and attenuation of edema. [2] [3] [4] Most of these findings, however, were made in single center, observational studies with small sample sizes and limited use of appropriate controls. Indepth, largescale, random ized, multicenter studies are merited to verify these findings and to further define the exact mechanisms of action of ACTH therapy.
Adverse effects of ACTH therapy Longterm (6-12 months) ACTH therapy is well tolerated in most patients with nephrotic syndrome. Noted adverse effects tend to be mild and are generally similar to those associated with glucocorticoid treat ment. 18, 29, 30 Most patients require potassium supplementation and some develop hyper tension. Serious allergic reactions (anaphy laxis) to ACTH therapy are rare, but have occurred in patients treated with ACTH gel for asthma and allergic conditions. 36 Skin pigmentation (bronze coloration) has been noted in some patients treated with synthetic ACTH 18,29,30 and a few treated with ACTH gel (A. S. Bomback, personal communication). Although the results of ongoing studies will help to elucidate potential adverse events associated with prolonged use of ACTH, a case series pub lished in 2011 13 reported that very few patients with nephrotic syndrome devel oped hyperglycemia (2 out of 21 patients), had significant weight gain or exhibited evi dence of accelerated bone loss after ACTH gel therapy. In most cases, adverse effects were tolerable and completely disappeared after the cessation of therapy.
Renoprotective mechanisms of ACTH ACTH was initially postulated to exert its beneficial effects indirectly, through its adrenal MC2Rmediated steroidogenesis, 3 as administration of glucocorticoids can also induce a similar remission of nephrotic syndrome. Emerging data, however, support the view that ACTH might have a protective effect on the kidney that is inde pendent of its steroidogenic action. This notion is based on the observation that in glomerular diseases, including IMN, treatment with steroids alone (even when administered at high doses) is unable to modify the natural course of the disease and has unproven benefit. 37 By contrast, ACTH monotherapy is effective in reduc ing proteinuria. 10, 29, 30 Additionally, in patients with steroid resistant nephrotic syndrome, ACTH treatment induces sat isfactory remission of proteinuria, 29, 31, 32 thereby suggesting the involvement of steroid independent mechanisms.
Direct effects on kidney cells
MCRs have been extensively studied in many animal and human organ systems. Little is known, however, about kidney specific MCR expression. Results in rodent studies vary: MC3R, MC4R and MC5R are expressed in the murine kidney, 14 whereas only MC1R and MC3R are expressed in the rat kidney. 15 My team has also clearly demonstrated the expression of MC5R in rodent podocytes, both in vivo and in vitro (Figure 2) . 11 In the human kidney, strong expression of MC5R and weak expression of MC2R have been demonstrated using PCR amplification of human kidneyspecific cDNA. 12 This finding is, to a certain extent, consistent with observations in sea bass, in which MC5R is abundantly expressed in both the anterior kidney and post erior kidney. 13 By contrast, MC1R expres sion (and, to a much lesser extent, MC4R expression) were detected by quantitative reverse transcriptase PCR in the human kidney and in cultured human podocytes, glomerular endothelial cells and tubular epithelial cells. 10 This discrepancy could reflect species differences but most probably relates to the potential pitfalls inherent in these detection technologies. As the MCRs are the product of small, intronless genes, genomic contamination complicates expres sion analysis based on reverse transcriptase PCR. 38 Nevertheless, if expression of MCRs in podocytes is verified, the antiproteinuric effect of ACTH might in fact be mediated by direct effects on these cells. 11 Tubular expression of MCRs also implies a possible mechanism for the effects of ACTH in AKI 26 or tubulointerstitial injury associated with glomerular diseases. 11 In addition, expression of MCRs in glomeru lar endothelial cells might also explain the potential actions of ACTH in patients with thrombotic microangiopathy caused by hemolyticuremic syndrome 39 and might also indicate a potential use for ACTH in other diseases of the glomerular endo thelium, including preeclampsia, throm botic thrombocytopenic purpura and transplant glomerulopathy.
Regardless of which types of MCR are expressed in this organ, a burgeoning body of evidence suggests that the kidney might be a direct effector organ of ACTH and other melanocortin peptides. ACTH might directly activate MCRs expressed on renal parenchymal cells and trigger downstream cellular effects (Table 1) which might exert downstream renoprotective effects, 7 includ ing inhibition of apoptosis, promotion of cell survival, reduction of inflammation and immunomodulation. 40 Immunomodulatory effects of ACTH Renal inflammation is an invariable pathologic finding in patients with various protein uric glomerulopathies. 41 Epidemiologic data suggest that renal inflammation is one of the few modifiable risk factors for longterm prog nosis and progression to endstage renal disease in most forms of proteinuric nephro pathies. 41 ACTH and other melano cortins, such as αMSH, have potent antiinflammatory actions in their target organs (including the
The melanocortin system is a hormone system that has an integral role in the homeostatic control of a diverse array of physiological functions, including pigmentation, inflammation, immunomodulation, steroidogenesis, energy homeostasis, sexual function and exocrine secretion. kidney) through multiple mechanisms. 40 The first involves the inhibition of pro inflammatory NFκB activation followed by reduced expression of NFκBdependent proinflammatory molecules, including interleukins, chemo kines and adhesion mol ecules. 40 The second involves the inhibition of migration and infiltration of inflamma tory cells, in particular macrophages. 11, 26 The third involves the suppression of inflammatory cell prolifera tion, possibly through inhibi tion of NFκB signaling 40 or through destabilization of cMyc via the cAMP-PKA-Akt-glycogen synthase kinase 3β pathway 42, 43 and the fourth involves an antioxidant effect. 44 Additionally, ACTH can modulate leuko cyte function and impair lymphocyte blasto genesis. 45, 46 Evidence also indicates that in human peripheral blood leukocytes, MCRs are abundantly expressed by B lympho cytes, 47 
CD4
+ Thelper cells, 48 natural killer cells, 48 monocytes and granulocytes. 48 ACTH can directly bind to immuno competent cells and modulate their immunoreactivity through functional MCRs. 49 These findings suggest that the effect of ACTH on immune complexmediated glomerulo pathies (such as IMN) and podocyto pathies (includ ing minimal change disease and FSGS) could result from its systemic immuno modulatory activities. These activities include reinstating the immune balance between subsets of Thelper cells; reducing autoantibody production; and diminishing the release of lymphokines that increase glomerular permeability. 50 The cholinergic antiinflammatory pathway 51 might also have a role in mediat ing the antiinflammatory effects of ACTH. In this pathway, vagus nerve signals modu late inflammation at various locations in the body through nicotinic acetylcholine recep tors, which are expressed by peripheral cells including kidney cells. 52 Data demonstrat ing a systemic protective effect of ACTH mediated through the central nervous system 53 suggest that an MCRmediated, vagal, cholinergic pathway is likely to con tribute, at least in part, to the renoprotective effect of ACTH.
Correction of dyslipidemia
Dyslipidemia has an important role in the development and progression of nephrotic glomerulopathies. 54 Lipidlowering drugs, such as statins, can also contribute to the amelioration of proteinuria, as shown by controlled trials in patients with IMN. [55] [56] [57] [58] Moreover, depletion of apolipoprotein J is a cause of proteinuric glomerulopathies, including membranous nephropathy and FSGS. 59 Consistent with this finding, apo lipoprotein supplementation can prevent glomerular permeability to albumin induced by serum from patients with FSGS in vitro. 60 As mentioned earlier, ACTH 1-24 has a pronounced lipidlowering effect even in healthy individuals. 17, 61 The mechanism responsible for this lipidmodifying activ ity has not been elucidated, but in vitro studies support the hypothesis that ACTH directly regulates hepatic lipoprotein metab olism. 17, 61 A possible interpreta tion of these studies is that by modifying apolipo protein metabolism, ACTH restores levels of certain apolipo proteins, including apolipo protein E or apolipo protein J. 30, 61 These apo lipoproteins might neutralize the activity of circulating permeability factors in patients with FSGS and thereby induce remission of proteinuria. 60 In addition, experimental studies demonstrated that apolipoprotein J competes with the termi nal components of complement (C5b-9) for the same receptor-namely megalin-in podocytes, 59 ,62 thereby attenuating glomeru lar injury and proteinuria in rat models of membranous nephropathy.
Conclusions
Clinical and experimental evidence sup ports a possible role for ACTH, with its antiproteinuric, lipid lowering and reno protective activities, as a novel therapy for treatmentrefractory nephrotic syndrome caused by a variety of glomerulopathies. ACTH might induce remission of nephrotic syndrome through a variety of potential mechanisms (Figure 3) , including (but not limited to) corticosteroidmediated pathways, the correction of dyslipidemia, through antiinflammatory effects on the central nervous system, through direct MCRmediated immunomodulation or by the direct MCRmediated protec tion of kidney cells, particularly of podo cytes. Although the existing findings are encouraging, most have been made in single center, observational studies with small sample sizes, limited controls and shortterm followup. Thus, a multicenter, random ized, controlled, doubleblind trial is the essential next step, to test the efficacy of ACTH therapy in patients with nephrotic syndrome. An extended followup duration is merited to assess whether ACTH therapy can actually retard the progression of CKD and stabilize kidney function, in addition to its proteinuriareducing effect.
ACTH, a wellknown treatment for lipoid nephrosis, is experiencing a revival and attracting much attention after 50 years of neglect. Future studies will help to elucidate how these mechanisms contribute to the efficacy of ACTH as an alternative option for patients with treatment refractory steroidsensitive and steroidresistant nephrotic syndrome. 
